ArticleCerebellum (London, England)2026
Spinocerebellar Ataxia Type 23 (SCA23): A Rare Cause of SCA in the Americas.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinocerebellar ataxia type 23 (SCA23) is a rare autosomal dominant hereditary ataxia caused by a pathogenic variant in the PDYN gene. It usually presents in adulthood, with a mean age of onset around 43 ± 15 years (reported range: 10–73 years), and progresses slowly with cerebellar symptoms. We report a case of a Brazilian 25-year-old female patient whose symptoms began at 19 years of age, characterized by progressive dysarthria, tremor, dysphagia, and gait disturbance. She had no relatives with similar symptoms. The initial genetic ataxia panel, which included the most prevalent hereditary ataxia genes, was negative. Subsequent next-generation sequencing identified a pathogenic variant in the PDYN gene, confirming the diagnosis of SCA23. Brain MRI demonstrated significant cerebellar atrophy. The patient was referred to a multidisciplinary rehabilitation group with emphasis on functional rehabilitation of gait and dysphagia. This case is notable for the rarity of SCA23 in the Americas, the relatively young age at onset compared with the reported mean age in the literature, while still remaining within the previously described age range, and the absence of a family history of ataxia or other neurological symptoms, despite SCA23 having an autosomal dominant inheritance pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.